World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Antimicrobial resistance is a major public health problem globally. Likewise, forms of tuberculosis (TB) resistant to first- and second-line TB medicines present a major challenge for patients, healthcare workers and healthcare services. In November 2019, the World Health Organization (WHO) convened an independent international expert panel to review new evidence on the treatment of multidrug- (MDR) and rifampicin-resistant (RR) TB, using the Grading of Recommendations Assessment, Development and Evaluation approach. Updated WHO guidelines emerging from this review, published in June 2020, recommend a shorter treatment regimen for patients with MDR/RR-TB not resistant to fluoroquinolones (of 9–11 months), with the inclusion of bedaquiline instead of an injectable agent, making the regimen all oral. For patients with MDR-TB and additional fluoroquinolone resistance, a regimen composed of bedaquiline, pretomanid and linezolid may be used under operational research conditions (6–9 months). Depending on the drug-resistance profile, extent of TB disease or disease severity, a longer (18–20 months) all-oral, individualised treatment regimen may be used. In addition, the review of new data in 2019 allowed the WHO to conclude that there are no major safety concerns on the use of bedaquiline for >6 months’ duration, the use of delamanid and bedaquiline together and the use of bedaquiline during pregnancy, although formal recommendations were not made on these topics. The 2020 revision has highlighted the ongoing need for high-quality evidence and has reiterated the need for clinical trials and other research studies to contribute to the development of evidence-based policy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A new tuberculosis treatment regimen for drug-resistant tuberculosis, endorsed by WHO, that is efficacious, safe, and shorter than previous regimens could have a role in reducing tuberculosis deaths.51”
From Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 (2024) · cites this paper as [51]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
What is ‘quality of evidence’ and why is it important to clinicians?
Guyatt, G. H., Oxman, A. D., Kunz, R., Vist, G. E., Falck-Ytter, Y., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39490.551019.be · Cited by 3,250
Sustainable Development Goals: Law, Theory and Implementation
(2018) · Edward Elgar Publishing eBooks · doi:10.4337/9781786438768 · Cited by 1,925
The World Health Organization Global Action Plan for antimicrobial resistance
Mendelson, M., & Matsoso, M. P. (2015) · South African Medical Journal · doi:10.7196/samj.9644 · Cited by 1,155
Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60570-0 · Cited by 1,117
Self-citationTreatment of Highly Drug-Resistant Pulmonary Tuberculosis
Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E., Moreira, J., Timm, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1901814 · Cited by 1,044
Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Van Deun, A., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., & Rieder, H. L. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0077oc · Cited by 647
Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J.-W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31644-1 · Cited by 632
Self-citationFinancial burden for tuberculosis patients in low- and middle-income countries: a systematic review
Tanimura, T., Jaramillo, E., Weil, D., Raviglione, M., & Lönnroth, K. (2014) · European Respiratory Journal · doi:10.1183/09031936.00193413 · Cited by 586
Self-citationTreatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Research works printed but not linked: 1
- Dooley K , Rosenkranz S , Conradie F , et al. QT effects of bedaquiline, delamanid or both in MDR-TB patients: the DELIBERATE trial. Conference on Retroviruses and Opportunistic Infections (CROI). Washington, USA. March 4–7, 2019. Available from: https://www.croiconference.org/abstract/qt-effects-bedaquiline-delamanid-or-both-mdr-tb-patients-deliberate-trial/
Cited by
The WHO Global Tuberculosis 2021 Report – not so good news and turning the tide back to End TB
Chakaya, J., Petersen, E., Nantanda, R., Mungai, B. N., Migliori, G. B., Amanullah, F., Lungu, P., Ntoumi, F., Kumarasamy, N., Maeurer, M., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.011 · Cited by 405
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis
Nyang’wa, B.-T., Berry, C., Kazounis, E., Motta, I., Parpieva, N., Tigay, Z., Solodovnikova, V., Liverko, I., Moodliar, R., Dodd, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117166 · Cited by 376
New developments in tuberculosis diagnosis and treatment
Gill, C. M., Dolan, L., Piggott, L. M., & McLaughlin, A. M. (2022) · Breathe · doi:10.1183/20734735.0149-2021 · Cited by 161
Ledesma, J. R., Ma, J., Zhang, M., Basting, A. V. L., Chu, H. T., Vongpradith, A., Novotney, A., LeGrand, K. E., Xu, Y. Y., Dai, X., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00007-0 · Cited by 146
“51 Additional research should examine the marked progress in reducing tuberculosis deaths in the 17 countries that achieved the End TB mortality milestone in 2020.”
World Health Organization treatment outcome definitions for tuberculosis: 2021 update
Nguyen, L. N., Viney, K. A., Gegia, M., Falzon, D., Glaziou, P., Floyd, K., Timimi, H., Ismail, N. A., Matteo Zignol, E., Kasaeva, T., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.00804-2021 · Cited by 141
Self-citation
Metadata
- Authors
- Mirzayev, F., Viney, K., Linh, N. N., Gonzalez-Angulo, L., Gegia, M., Jaramillo, E., Zignol, M., & Kasaeva, T.
- Affiliations
- World Health Organization (CH)
- Corresponding author
- Mirzayev, Fuad
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2020-11-26
- Volume
- 57
- Issue
- 6
- Pages
- 2003300
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC8176349
- OpenAlex
- W3108150642
- Cited by
- 301
- References
- 23
- Citations by year
- 2026: 31 · 2025: 53 · 2024: 43 · 2023: 88 · 2022: 64 · 2021: 22
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Respiratory Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- United States Agency for International Development
- Russian Federation
- Unitaid
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- drug-resistant tuberculosis, multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis, bedaquiline, pretomanid, linezolid, delamanid, fluoroquinolone resistance, treatment duration, WHO treatment recommendations, antimicrobial resistance
- MeSH terms
- Linezolid, Antitubercular Agents, Drug Therapy, Combination, Female, Humans, Pregnancy, World Health Organization, Tuberculosis, Multidrug-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. https://app.cochat.ai/papers/10.1183/13993003.03300-2020
- The paper
- Mirzayev, F., Viney, K., Linh, N. N., Gonzalez-Angulo, L., Gegia, M., Jaramillo, E., Zignol, M., & Kasaeva, T. (2021). World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. European Respiratory Journal. https://doi.org/10.1183/13993003.03300-2020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
